Subscribe to RSS
DOI: 10.1055/s-0028-1090089
© Georg Thieme Verlag KG Stuttgart · New York
Gamma-Hydroxybutyrat (GHB)-Abhängigkeit und -Entzug bei vorbestehender Alkoholabhängigkeit
Gamma-Hydroxybutyrat (GHB)-Dependence and -Withdrawal in the Case of Previous Alcohol DependencePublication History
Publication Date:
27 January 2009 (online)

Zusammenfassung
Anliegen In dieser Kasuistik werden die Entwicklung einer γ-Hydroxybutyrat-Abhängigkeit und deren stationäre Entgiftung vor dem Hintergrund einer primär bestehenden Alkoholabhängigkeit beschrieben. Methode Es werden Ausgangslage, psychopathologischer Befund und Verlauf der Entgiftung beschrieben. Ergebnisse / Schlussfolgerung Die kombinierte Entgiftung von GHB und Alkohol erfolgte mit einem Diazepam-Reduktionsschema. Die für die Alkoholentgiftung etablierten Entzugsskalen waren mit Einschränkungen hilfreich. Bei dem Patienten liegt nach ICD-10 eine Polytoxikomanie vor.
Abstract
Objective γ-Hydroxybutyrat (GHB) is used medically for narcolepsy and as a narcotic. It is also a rare illegal drug. In this case report the development of a GHB-dependency against the background of a primary alcohol dependency is described. Methods Based on established alcohol withdrawal scales (AWSS by Wetterling, CIWA) and neuropsychological testing procedures (CGI, GAF, SKID-II, PISQ, analog-scale for Craving), the initial situation, the development of psychopathological findings, and the course of detoxification were shown. Results / Conclusion The combined detoxication of GHB and alcohol was successfully finished by a reduction schedule of diazepam. Withdrawal-assessment scales for alcohol were helpful, but show limitations for GHB-withdrawal symptoms. The patient suffers, according to ICD-10, from a multiple drug dependence (alcohol, GHB, abstinence from amphetamines). Symptoms of insomnia, major depression, and generalized anxiety disorder can be associated with the use of GHB.
Schlüsselwörter
GHB - Abhängigkeit - Entgiftung - Alkohol - Entgiftung
Key words
GHB - dependence - detoxification - alcohol - withdrawal
Literatur
- 1 Die Drogenbeauftragte der Bundesregierung .Drogen – und Suchtbericht. April 2004. Mai 2005
- 2 Nicholson K, Balster R. GHB – a new and novel drug of abuse. Drug Alcohol Depend. 2001; 63 1-22
- 3 Halkitis P N, Palamar J J, Mukherjee P P. Poly-club-drug use among gay and bisexual men – A longitudinal analysis. Drug Alcohol Depend. 2007; 89 153-160
- 4 McDaniel C, Miotto K A. Gamma hydroxybutyrate (GHB) and gamma butyrolactone (GBL) withdrawal – five case studies. J Psychoactive Drugs. 2001; 33 (2) 143-149
- 5 Bennett W R, Wilson L G, Roy-Byrne P P. Gamma-hydroxybutyric acid (GHB) withdrawal: a case report. J Psychoactive Drugs. 2007; 39 293-296
- 6 Liechti M E. et al . Clinical features of gamma-hydroxybutyrate and gamma-butyrolactone toxicitiy and concomitant drug and alcohol use. Drug Alcohol Depend. 2005; 81 232-326
- 7 Andresen H. et al . Liquid Ecstasy – ein relevantes Drogenproblem. Dtsch Ärztebl. 2008; 105 (36) 599-603
- 8 Sumnall H R. et al . Use, function, and subjective experiences of gamma-hydroxybutyrate (GHB). Drug Alcohol Depend. 2008; 1 286-290
- 9 Nimmerrichter A, Walter H, Gutierrez-Lobos K E. et al . Double-blind controlled trial of γ-Hydroxybutyrate and Clomethiazole in the treatment of alcohol withdrawal. Alcohol Alcohol. 2001; 37 67-73
- 10 Kim S Y. et al . High-risk behaviors and hospitalizations among gamma hydroxybutyrate (GHB) users. Am J Drug Alcohol Abuse. 2007; 33 429-438
- 11 Wrase J. et al . Serotonergic dysfunction – brain imaging and behavioral correlates. Cogn Affect Behav Neurosci. 2006; 6 53-61
- 12 Abanades S. et al . Relative abuse liability of gamma-hydroxybutyric acid, flunitrazepam, and ethanol in club drug users. J Clin Psychopharmacol. 2007; 27 625-638
- 13 Trendelenburg G, Ströhle A. Gamma-hydroxybutyrate – a neurotransmitter, medicine, and drug. Nervenarzt. 2005; 76 832-838
- 14 Kim S. et al . Systematic assessment of gamma hydroxybutyrate (GHB) effects during and after acute intoxication. Am J Addict. 2008; 17 (4) 312-318
- 15 McDonough M. et al . Clinical features and management of gamma-hydroxybutyrate withdrawal-a review. Drug Alcohol Depend. 2004; 75 3-9
- 16 Sivilotti M. et al . Pentobarbital for severe gamma-butyrolactone withdrawal. Ann Emerg Med. 2001; 38 (6) 660-665
Dr. med. Christoph Richter, MBA
Vivantes Wenckebach-Klinikum, Klinik für Psychiatrie, Psychotherapie und Psychosomatik – Gerontopsychiatrie
Wenckebachstraße 23
12099 Berlin
Email: ch.richter@charite.de